Comprehensive Outcome Measures and Perioperative Morbidity After Cystectomy

Comprehensive Outcome Measures and Perioperative Morbidity After Cystectomy - COMPACT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00024929

Enrollment

200

Registered

2022-01-24

Start date

2020-05-07

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C67

Interventions

Group 1: Radical cystectomy or cystoprostatectomy ± pelvic lymph node dissection ± anterior exenteration and urinary diversion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients capable of giving consent =18 years undergoing radical cystectomy (with anterior exenteration if necessary) or cystoprostatectomy with urinary diversion.

Exclusion criteria

Exclusion criteria: Patients unable to give informed consent, pregnant women and minors <18 years of age

Design outcomes

Primary

Measure	Time frame
(1) Perioperative and long-term morbidity: - Clavien-Dindo classification - Comprehensive Complication Index® (assessment at 30 and 90 days as well as at 12 months) (2) Functional, patient-centered outcomes / Patient-reported Outcome Measures (PROMs): - FACT-Bl-Cys - EORTC QLQ-C30 / QLQ-BLM-30 (assessment preoperatively, at 30 and 90 days, at 6, 12, and 24 months) (3) Oncological outcomes: - Overall survival - Cancer-specific survical - Disease-free survival (assessment at 90 days, 6, 12, and 24 months)	—

Measure

Time frame

(1) Perioperative and long-term morbidity: - Clavien-Dindo classification - Comprehensive Complication Index® (assessment at 30 and 90 days as well as at 12 months) (2) Functional, patient-centered outcomes / Patient-reported Outcome Measures (PROMs): - FACT-Bl-Cys - EORTC QLQ-C30 / QLQ-BLM-30 (assessment preoperatively, at 30 and 90 days, at 6, 12, and 24 months) (3) Oncological outcomes: - Overall survival - Cancer-specific survical - Disease-free survival (assessment at 90 days, 6, 12, and 24 months)

—

Countries

Germany

Contacts

Public ContactMara Kölker

Klinik und Poliklinik für Urologie, Universitätsklinikum Hamburg-Eppendorf

m.koelker@uke.de+49 (0) 40 7410 - 53445

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026